BUDZ — what changed in the latest 10-Q
A section-by-section comparison of BUDZ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +13 | −5 | ~54 | 120 |
| Market risk (Item 3) | Text added/removed | +13 | −5 | ~54 | 119 |
| Controls & procedures | Text added/removed | +13 | −5 | ~54 | 119 |
| Legal proceedings | Text added/removed | +13 | −5 | ~54 | 119 |
| Risk factors | Some risk factors updated | +13 | −5 | ~54 | 119 |
| Other information | Text added/removed | +13 | −5 | ~54 | 119 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice